SIVA, a target of p53, is downregulated in myelodysplastic syndromes

Applied Cancer Research

Table 3 Univariate and multivariate analyses of survival outcomes for MDS patients

Factor	Univariate analysis						Multivariate analysis
	Event Free Survival			Overall Survival			Event Free Survival			Overall Survival
	Hazard Ratio^b	(95% C.I.)	p	Hazard Ratio^b	(95% C.I.)	p	Hazard Ratio^b	(95% C.I.)	p	Hazard Ratio^b	(95% C.I.)	p
Gender
Male vs. female	1.92	0.97–3.80	0.06	2.26	1.09–4.59	0.02	3.07	1.44–6.58	0.002	3.29	1.48–7.35	0.002
Age at sampling	1.01	0.99–1.04	0.28	1.01	0.99–1.04	0.31	-	-	-	-	-	-
WHO 2008 classification
RAEB-1/RAEB-2 vs. others	5.12	2.58–10.17	<0.0001	3.95	1.94–8.06	0.002	8.54	3.66–19.93	<0.0001	6.03	2.58–14.09	0.0004
Risk Stratification by IPSS-R^a
Intermediate/High/Very high vs. Very low/Low	2.17	1.18–4.34	0.01	2.04	1.04–4.01	0.04	-	-	-	-	-	-
SIVA1 expression	1.07	0.87–1.32	0.52	1.05	0.85–1.30	0.62	-	-	-	-	-	-
SIVA2 expression	1.05	0.94–1.17	0.35	1.03	0.92–1.14	0.59	-	-	-	-	-	-
MDM2 expression	0.80	0.63–1.01	0.06	0.79	0.62–1.02	0.07	-	-	-	-	-	-
TP53 expression	1.02	0.97–1.08	0.46	1.02	0.96–1.09	0.43	-	-	-	-	-	-

Abbreviations: MDS myelodysplastic syndromes, WHO World Health Organization, RAEB-1 refractory anemia with excess blast-1, RAEB-2 refractory anemia with excess blast-2, R-IPSS Revised International Prognostic Scoring System
^aMetaphase cytogenetic was not available in three patients
^bHazard ratios >1 indicate that the first factor has the poorer outcome